Literature DB >> 1689275

Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene.

J M Styles1, S Harrison, B A Gusterson, C J Dean.   

Abstract

With the breast carcinoma cell line BT 474 used as a source of antigen, four rat monoclonal antibodies (MAbs) (3 IgG2a and I IgA) have been prepared against the external domain of the product of the c-erbB-2 proto-oncogene. All 4 antibodies stain frozen sections of tissues that over-express the product of the c-erbB-2 proto-oncogene, and competitive binding assays showed that the antibodies recognized 2 non-overlapping epitopes. Representative antibodies from the two groups (ICR12 and 13) were shown to specifically immunoprecipitate a 190 kDa protein from 35S-methionine-labelled breast carcinoma cells where the c-erbB-2 is amplified (BT 474 and MDA-MB 361). Two of the antibodies (ICR12 and ICR17) bind to the denatured antigen in Western blots and ICR12 stains formolsaline-fixed sections of breast carcinoma tissue that over-expresses the product of the c-erbB-2 proto-oncogene. These antibodies should be useful not only for immunocytochemical diagnoses but also for radio-immunoscintigraphic and therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689275     DOI: 10.1002/ijc.2910450219

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Protein-based tumor molecular imaging probes.

Authors:  Xin Lin; Jin Xie; Xiaoyuan Chen
Journal:  Amino Acids       Date:  2010-03-17       Impact factor: 3.520

2.  Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2.

Authors:  S M Allan; C J Dean; S Eccles; N P Sacks
Journal:  Cell Biophys       Date:  1994

3.  Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands.

Authors:  P O-charoenrat; P Rhys-Evans; W J Court; G M Box; S A Eccles
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

4.  Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.

Authors:  I N Fernando; T J Powles; M Dowsett; S Ashley; L McRobert; J Titley; M G Ormerod; N Sacks; M C Nicolson; A Nash
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.

Authors:  Abbas Ghaderi; Mohammad Vasei; S A Maleck-Hosseini; Behronz Gharesi-Fard; Maliheh Khodami; Mehrnoosh Doroudchi; Helmout Modjtahedi
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

6.  Pregnancy and breast cancer: a population-based study.

Authors:  W Reed; E Hannisdal; E Skovlund; S Thoresen; P Lilleng; J M Nesland
Journal:  Virchows Arch       Date:  2003-05-20       Impact factor: 4.064

7.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.

Authors:  J E Somerville; L A Clarke; J D Biggart
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

8.  Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.

Authors:  C J Dean; S A Eccles; M Valeri; G Box; S Allan; C McFarlane; J Sandle; J Styles
Journal:  Cell Biophys       Date:  1993 Jan-Jun

9.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

10.  Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.

Authors:  S M Allan; C Dean; I Fernando; S Eccles; J Styles; V R McCready; M Baum; N Sacks
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.